SCM
CERO

Shaolin Capital Management’s CERo Therapeutics CERO Stock Holding History

Shaolin Capital Management’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-54
Closed -$1.19M – 626
2023
Q2 		$1.19M Buy
+54
New +$1.17M 0.04% 238

Other funds holding CERO

MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 19.06% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $639M AUM 31.05% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

Shaolin Capital Management's CERO Position: Q4 2023 in Review

Shaolin Capital Management sold out of CERo Therapeutics (CERO) in Q4 2023, closing a stake of 25 shares — an estimated $543K sold.

Shaolin Capital Management first reported a position in CERO in Q3 2022 and held it in 4 quarters. The position peaked at $1.04M in Q1 2023. 9 funds tracked by Wall St. Rank hold CERO as of Q4 2023.

  • Shaolin Capital Management reported no remaining CERo Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Shaolin Capital Management sold 25 CERo Therapeutics shares in Q4 2023, an estimated $543K.
  • Shaolin Capital Management first reported a position in CERo Therapeutics in Q3 2022 and held it in 4 quarters.
  • Shaolin Capital Management's CERo Therapeutics position peaked at $1.04M in Q1 2023.
  • 9 funds tracked by Wall St. Rank held CERo Therapeutics as of Q4 2023.

Based on Shaolin Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.